Tivic Health

Biotechnology ResearchCalifornia, United States11-50 Employees

Tivic is an immunotherapy company whose lead-drug candidate is Entolimod™ to treat Acute Radiation Syndrome (ARS) is in late-stage development. Entolimod™ is a TLR5 agonist that activates an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The pipeline includes Entolimod™ to treat neutropenia, and lymphocyte exhaustion, as well as Entolasta™, an immunologically optimized variant of Entolimod™ for chronic applications.

Tivic’s wholly owned subsidiary, Velocity Bioworks, is a full-service contract development and manufacturing organization (CDMO) based in San Antonio. Tivic also uses Velocity Bioworks’ manufacturing services to advance its own drug pipeline with the benefit of lowered costs, eliminated delays sometimes associated with outsourcing, and accelerated manufacturing processes.

To learn more about Tivic, visit: https://ir.tivichealth.com

Sign up for free to view info

Email Format Employee directory